Bloom Energy Achieves First-Ever Positive EPS with Revenue Surge

Published 13 hours agoBE

Bloom Energy Achieves First-Ever Positive EPS with Revenue Surge

Bloom Energy Corporation has marked a significant financial milestone by reporting its first-ever positive earnings per share (EPS) for the first quarter, accompanied by a 39% year-over-year revenue growth. This achievement reflects the company's strong demand and operational efficiency.

Further bolstering its financial performance, Bloom Energy noted an improvement in gross margins and successfully reduced operating expenses by $21 million compared to the previous year. The company's financial health was also supported by generating $484.2 million in cash flow from operating activities. In addition, international expansion efforts in markets like Korea and Italy have further driven growth.

In 2024, Bloom Energy's service business reached profitability, contrasting with a $33 million loss the previous year, and achieved a $4 million full-year non-GAAP gross profit. The company has set its sights on a revenue target of $1.4 billion to $1.6 billion for 2025 and a non-GAAP operating profit of $75 million to $100 million, as reported by Bloomberg Energy.

Share this article

Twitter Facebook LinkedIn

Recent Articles

United Airlines Slashes Over 700 Newark Flights Amid FAA Staffing Strains

United Airlines Slashes Over 700 Newark Flights Amid FAA Staffing Strains

2 minutes agoUAL

United Airlines is set to reduce its flight schedule significantly at Newark Liberty International Airport in November 2023, citing persistent FAA staffing shortages and technical glitches. This decision will see more than 700 flights, mostly domestic short- and medium-haul routes, cut from its Newark hub, as reported by simpleflying.com. The move highlights the ongoing challenges faced by airlines operating under constrained resources. These changes come in response to repeated reductions in traffic flow to Newark by the FAA due to low staff numbers, leading to notable disruptions. Reuters noted that the FAA's staffing situation is currently about 3,500 air traffic controllers short of its target, a result of a 10% decrease since 2012. This shortage has caused existing employees to work extended hours, which has only been compounded by outdated infrastructure, some of which is over 60 years old. In response to these challenges, major U.S. airlines, including United, have sought extensions to the current waivers on minimum flight requirements at crowded New York City-area airports through October 2027, according to Reuters. These steps aim to accommodate both the ongoing staffing and technological setbacks facing the FAA, underscoring the urgent need for enhanced staffing and upgrading of infrastructure to maintain efficient air travel services.

Inspire Medical Systems Awaits Q1 2025 Earnings Release

Inspire Medical Systems Awaits Q1 2025 Earnings Release

17 minutes agoINSP

As of May 2, 2025, Inspire Medical Systems has not yet released its earnings report for Q1 2025. Historically, the company announces its quarterly results about a month after the period ends, which suggests that investors can expect the report in early June 2025. This timing has see investors keen to understand how the company's recent financial growth trends will continue. Inspire Medical's Q4 2024 results showed robust performance, with revenue reaching $239.7 million, marking a 25% increase compared to the previous year. The company also reported a gross margin of 85.0% and a net income of $35.2 million. The diluted earnings per share stood at $1.15. During the same quarter, Inspire activated 72 new U.S. centers, raising the total number to 1,435, and generated an operating cash flow of $69.2 million. Looking at the full year 2024, Inspire posted a revenue of $802.8 million, a 28% rise from the previous year. The company is targeting a revenue range of $940 million to $955 million for 2025, indicating a 17% to 19% growth year-over-year. Inspire's guidance for diluted EPS is between $2.10 and $2.20. Reuters noted that these figures underscore the company's positive trajectory as stakeholders anticipate its forthcoming disclosures.

Nine Energy Faces NYSE Non-Compliance Notice

Nine Energy Faces NYSE Non-Compliance Notice

32 minutes agoNINE

Nine Energy Service, Inc., listed on the NYSE under the symbol NINE, has received a notification from the New York Stock Exchange as of October 21, 2024, regarding its failure to meet certain listing criteria. The issue stems from the company's average global market capitalization and stockholders' equity falling below $50 million over a 30-day period. According to a report from Businesswire, Nine Energy Service has 45 days to put forward a plan to the NYSE, outlining how it will achieve compliance within the next 18 months. Should the NYSE accept their strategy, the company's shares will continue to be traded, albeit with quarterly reviews. Failing to meet the outlined standards, however, could trigger steps towards delisting from the exchange. Despite this notice, Nine Energy Service's core business operations remain unaffected by the NYSE's compliance concerns. The notice has not impacted their SEC filings nor triggered any defaults on major debts or agreements. Nonetheless, the announcement led to a roughly 4% dip in their stock price, which was trading at 98 cents per share, noted TradingView.

Liquidia's Stock Jumps 12% After Supreme Court Decision

Liquidia's Stock Jumps 12% After Supreme Court Decision

47 minutes agoLQDA

Liquidia Technologies' stock saw a significant 12% increase, climbing to $11.20, after the U.S. Supreme Court declined to review an appeal concerning the '793 patent of rival United Therapeutics on October 7, 2024. This decision effectively invalidates the patent, eliminating a major hurdle for Liquidia's Yutrepia product, as reported by marketscreener.com. The Supreme Court's move is a breakthrough for Liquidia, which is gearing up for Yutrepia's entry into the market. Yutrepia, approved tentatively by the FDA for treating adults with specific types of pulmonary hypertension, is awaiting final approval, anticipated once a competing product's exclusivity expires in May 2025. In light of the Supreme Court ruling, BTIG analysts have reaffirmed a "Buy" rating for Liquidia with a $25.00 price target, suggesting that the decision plays a crucial role in clearing Yutrepia's path to the market. Liquidia is now better positioned to compete with United Therapeutics' Tyvaso, which currently holds a significant market share. The Supreme Court ruling may expedite Yutrepia's market availability, allowing Liquidia to potentially attract customers from Tyvaso, pushing forward the company's strategic plans for a successful product launch.